CRISPR therapies march into clinic, but genotoxicity concerns linger
By Cormac Sheridan,
Nature
| 07. 15. 2021
A recent study has identified another potential hazard for developers of genome editing therapies based on CRISPR–Cas9. The double-strand DNA breaks introduced during CRISPR editing could result in chromothripsis, an extremely damaging form of genomic rearrangement that results from the shattering of individual chromosomes and the subsequent rejoining of the pieces in a haphazard order. Although most cells do not remain viable after undergoing such a dramatic alteration, those that do could, in theory, express oncogenic fusion proteins or give rise to dysregulated expression of particular genes that could cause problems.
So far, none of the companies leading the clinical development of CRISPR-based therapies appears to have considered the issue; its clinical implications, if any, remain unclear. However, the study, led by Mitchell Weiss of St. Jude Children’s Research Hospital and David Pellman of the Dana–Farber Cancer Institute and Harvard Medical School, adds another layer of complexity to gene-editing’s already relatively complicated mechanism of action. “Most importantly, it’s an on-target effect. You cannot make this go away by making the cutting more specific,” says Pellman.
The study is the...
Related Articles
GeneWatch UK has prepared a briefing on the genetic modification of nature for the International Union for Conservation of Nature (IUCN) Congress in October 2025
The upcoming Congress claims to be “where the world comes together to set priorities and drive conservation and sustainable development action.” A major concern for those on the outside is that the Congress may advance plans to develop and encourage the use of synthetic biology in nature conservation. This could at first glance sound like...
By Aaron Ginn, The Washington Post | 09.12.2025
Earlier this year, I had dinner in D.C. with Jensen Huang, the president and chief executive of Nvidia. At one point, he said something that struck me: “Why is everyone here so negative?”
He wasn’t referring to the economy...
By Roni Caryn Rabin, The New York Times | 08.25.2025
Scientists have dreamed for centuries about using animal organs to treat ailing humans. In recent years, those efforts have begun to bear fruit: Researchers have begun transplanting the hearts and kidneys of genetically modified pigs into patients, with varying degrees...
The Center for Genetics and Society is delighted to recommend the current edition of GMWatch Review – Number 589. UK-based GMWatch, a long-standing ally, was founded in 1998 by Jonathan Matthews as an independent organization seeking to counter the enormous corporate political power and propaganda of the GMO industry and its supporters. Matthews and Claire Robinson are its directors and managing editors.
CGS works to ensure that social justice, equity, human rights, and democratic governance are front...